Discontinued — last reported Q3 '21
Vertex Pharmaceuticals OCI Before Reclassifications, Net of Tax remained flat by 0.0% to -$48.33M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 215.1%, from $42.00M to -$48.33M. Over 2 years (FY 2023 to FY 2025), OCI Before Reclassifications, Net of Tax shows a downward trend with a 374.1% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Positive trends suggest favorable movements in currency or debt markets that are not yet realized in earnings.
Measures the total change in equity from non-owner sources that is excluded from net income, calculated before any recla...
Standard reporting component for all companies with international operations or significant debt portfolios.
is_tmo_oci_before_reclassifications_net_of_tax| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $8.60M | $168.00M | -$193.30M |
| YoY Change | — | >999% | -215.1% |
We use cookies for analytics. See our Privacy and Cookie Policy.